
METABOLIC OUTCOMES AMONG SCHIZOPHRENIA AND BIPOLAR DISORDER PATIENTS

A. Ventriglio¹, A. Gentile¹, R.J. Baldessarini², S. Martone¹, G. Vitrani¹, A. La Marca¹, A. Bellomo¹

¹University of Foggia Department of Clinical and Experimental Medicine Section of Psychiatry Foggia Italy, University of Foggia, Foggia, Italy ;

²Department of Psychiatry Harvard Medical School International Consortium for Bipolar and Psychotic Disorders Research McLean Hospital Belmont Massachusetts USA., Harvard Medical School, Boston, USA

Purpose: As weight-gain and metabolic abnormalities during treatment with psychotropic drugs are of great concern, we evaluated effects of psychoeducation and medical monitoring on metabolic changes among severely mentally ill patients.

Materials and Methods: During repeated, systematized psychoeducation about physical health among 66 consecutive patients diagnosed with DSM-IV schizophrenia (SZ; n=33) or type-I bipolar disorder (BD; n=33), we evaluated (at intake, 1, 2, 3, and 6 months) clinical psychiatric status, treatments and doses, rated drugs- attitude of patients, and recorded physiological parameters.

Results: At intake, BD vs. SZ patients were receiving 3–7-times more psychotropic medication, with correspondingly higher initial body-mass index (BMI: 29.1 vs. 25.6 kg/m²), 12-times more obesity, and significantly higher serum lipid concentrations. During 6-month follow-up, ratings of drugs- attitude of patients improved, polytherapy decreased in BD, and BMI decreased slightly, as serum lipid concentrations declined continuously (e.g., total cholesterol+triglycerides: BD by 3.21 > SZ by 1.75%/month). Declining lipid levels were associated with: [a] older age, [b] BD diagnosis, [c] being unemployed, [d] higher antipsychotic dose, [e] lower initial BPRS scores (all $p \leq 0.001$).